78754-81-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloroquinazoline-2,4-diol is used as a potential active pharmaceutical ingredient for its potential biological activities. Given the general properties of quinazolines, it may be employed as an anticancer, antiviral, or anti-inflammatory agent. However, the actual properties, uses, and effects of this specific compound would need to be determined through laboratory study and research.
Used in Research and Development:
5-Chloroquinazoline-2,4-diol is used as a chemical intermediate or a starting material in the synthesis of more complex molecules with potential pharmaceutical applications. Its role in research and development is to facilitate the discovery of new drugs and therapeutic agents.
Used in Drug Discovery:
5-Chloroquinazoline-2,4-diol is used as a scaffold in drug discovery, where it may be modified to create new compounds with improved pharmacological properties. The exploration of its chemical structure can lead to the development of novel therapeutic agents with specific targets in medicine.
Note: The uses mentioned above are speculative and based on the general properties of quinazolines. The actual applications of 5-chloroquinazoline-2,4-diol would need to be confirmed through scientific research and clinical trials.

InChI:InChI=1/C8H5ClN2O2/c9-4-2-1-3-5-6(4)7(12)11-8(13)10-5/h1-3H,(H2,10,11,12,13)

Upstream product

• 2148-56-3 2-chloro-6-aminobenzoic acid 
• 57-13-6 urea 
• 590-28-3 potassium cyanate 
• 6575-11-7 2-amino-6-chlorobenzonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 124-38-9 carbon dioxide 
• 192570-28-8 2-ureido-6-chlorobenzoic acid 
• 54166-95-9 2-amino-6-chlorobenzamide 

Downstream Products

• 134517-55-8 2,4,5-trichloroquinazoline 
• 192570-37-9 1-(3,5-di-O-p-toluoyl-2-deoxy-α,β-D-erythro-pentofuranosyl)-5-chloro-quinazoline-2,4(3H)-dione 
• 121496-98-8 6,8-Diethyl-2-phenyl-1,6-dihydro-imidazo[4,5-f]quinazoline-7,9-dione 
• 121496-97-7 6,8-Dimethyl-2-phenyl-1,6-dihydro-imidazo[4,5-f]quinazoline-7,9-dione 
• 192570-52-8 1-[2-deoxy-5-(4,4'-dimethoxytrityl)-β-D-erythro-pentofuranosyl]-5-chloro-quinazoline-2,4(3H)-dione 
• 192570-57-3 1-[2-deoxy-5-(4,4'-dimethoxytrityl)-α-D-erythro-pentofuranosyl]-5-chloro-quinazoline-2,4(3H)-dione 

Relevant academic research and scientific papers

Preparing method for quinazoline nucleoside derivative

The invention aims at providing a method of obtaining a quinazoline nucleoside derivative provided with different substitutes through a three-step reaction by adopting an o-aminobenzoic acid derivative as a material. The method is characterized by comprising the steps of 1, adopting glacial acetic acid and 2-amidogen-6- replacing benzoic acid as raw materials to obtain 5-repalcing-quinazoline-2, 4-dione, wherein the reaction time is 3-5 hours, and obtaining an intermediate product through purification; 2, making the obtained product in the last step, NO-BSA, 1-acetoxyl group-2,3,5-tri-o-benzoyl-beta-d-ribofuranose and TMSOTf react for 20-24 hours in acetonitrile, and obtaining a nucleoside derivative coarse product through purification; 3, adding the product obtained in the last step and methyl alcohol to a high-pressure reaction tube to be subjected to ammonolysis for 20-24h hours, and obtaining a final product through column chromatography separation purification. The quinazoline nucleoside derivative obtained through the method has good prospects in multiple fields of biology, medicine and the like.

SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF

The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses； wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

Synthesis and Characterization of Amidato Divalent Lanthanide Complexes and Their Use in Forming 2,4-Quinazolidinones from CO2 and 2-Aminobenzonitriles

Four amidato divalent lanthanide complexes, {LnLn[N(TMS)2]THF}2 [n = 1, Ln = Eu (1); n = 2, Ln = Eu (3), Yb (4); HL1 = tBuC6H4CONHC6H3(iPr)2; HL2 = C6H5CONHC6H3(iPr)2] and {L3Eu[N(TMS)2]THF}{L32Eu(THF)2} (2) [HL3 = ClC6H4CONHC6H3(iPr)2], were synthesized and extensively characterized. This is the first time that the amidato lanthanide amides 1-4 were used to catalyze the reactions of CO2 and 2-aminobenzonitriles to form quinazoline-2,4(1H,3H)-diones at atmospheric pressure. All the complexes efficiently catalyzed the transformation, with complex 3 showing the highest activity. This catalytic system gave good to excellent yields, and good functional group tolerance. Preliminary studies were conducted to investigate the reaction mechanism.

Carbon Dioxide Mediated Novel Synthesis of Quinazoline-2,4(1H,3H)-dione in Water

A novel, efficient, and scalable CO2 mediated synthesis of quinazoline-2,4(1H,3H)-dione was developed by a simple cyclization of 2-aminobenzonitrile with DMF in water as the solvent. This is the first report of its kind. DMF was used as the necessary carbon source in the synthesis of quinazoline-2,4(1H,3H)-dione. This synthetic protocol is very efficient; it gives >99% conversion with excellent selectivity. The product was isolated by filtration because of the highly insoluble nature of quinazoline-2,4(1H,3H)-dione in water. The co-product, dimethyl amine, also has industrial importance, and the CO2 that is used can be recycled. This protocol has wide-spread applications in the syntheses of benzimidazole and benzothiazole.

Antileishmanial activity of a series of N2, N 4-disubstituted quinazoline-2,4-diamines

A series of N2,N4-disubstituted quinazoline-2,4- diamines has been synthesized and tested against Leishmania donovani and L. amazonensis intracellular amastigotes. A structure-activity and structure-property relationship study was conducted in part using the Topliss operational scheme to identify new lead compounds. This study led to the identification of quinazolines with EC50 values in the single digit micromolar or high nanomolar range in addition to favorable physicochemical properties. Quinazoline 23 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37% when given by the intraperitoneal route at 15 mg kg-1 day-1 for 5 consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable physicochemical properties make the N2,N 4-disubstituted quinazoline-2,4-diamine compound series a suitable platform for future development of antileishmanial agents.

USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS

Compounds of a compound of compound of general formula (I) wherein X1, X2, A, R1R2, R3 and R4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.

METHOD OF TREATING BRAIN CANCER

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.

COMPOUNDS AND THERAPEUTICAL USE THEREOF

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

Tripler stability of oligodeoxynucleotides containing substituted quinazoline-2,4-(1H,3H)-dione

Triple helical structures can be observed between double-stranded nucleic acids and a third strand through the formation of Hoogsteen hydrogen bond. We report here the use of quinazoline-2,4-dione derivatives as substitutes for thymine in TA*T triplets. The synthesis and the characterization of monochloro derivatives of quinazoline-2,4-dione as well as 5-fluoro and 6-nitro substituted quinazoline rings are described. The ability of the various modified bases to promote the formation of triplexes was reached by thermal denaturation studies.